2026-01-23 - Analysis Report
**1. Company Overview**
Amgen is a biotechnology firm that specializes in developing and producing pharmaceuticals, vaccines, and other biotechnology products.

**2. Return Rate Comparison**
| Ticker & Company | Cumulative Return Rate |
| --- | --- |
| AMGN (Amgen) | 79.62% |
| VOO (S&P 500) | 92.53% |

**Divergence:** The divergence between AMGN and VOO is -22.30, indicating that AMGN's cumulative return rate is lower than that of VOO.

**Relative Divergence:** The relative divergence is 32.90%, indicating that AMGN is currently located at the lower end of the past data fluctuation range.

**3. Alpha, Beta Analysis**
| Year | CAGR | MDD | Alpha | Beta | Market Cap (B) |
| --- | --- | --- | --- | --- | --- |
| 2016-2018 | 14.0% | 14.6% | 10.0% | 1.1 | 104.8B |
| 2017-2019 | 41.0% | 12.4% | 23.0% | 0.9 | 129.8B |
| 2018-2020 | 8.0% | 17.7% | -13.0% | 0.8 | 123.8B |
| 2019-2021 | 15.0% | 17.7% | -28.0% | 0.8 | 121.1B |
| 2020-2022 | 15.0% | 15.5% | 17.0% | 0.6 | 141.4B |
| 2021-2023 | 19.0% | 15.3% | 19.0% | 0.4 | 155.1B |
| 2022-2024 | 12.0% | 21.0% | -8.0% | 0.4 | 140.3B |
| 2023-2025 | 38.0% | 21.0% | -24.0% | 0.5 | 176.2B |

**4. Recent Stock Price Fluctuations**
| SMA | Value |
| --- | --- |
| 5-day SMA | $336.42 |
| 20-day SMA | $331.07 |
| 60-day SMA | $326.86 |
| Close | $347.07 |
| Last-Market | $344.8 (previous close: $343.6, change: $1.2) |

**5. RSI, PPO Index Indicators**
| Indicator | Value |
| --- | --- |
| RSI | 64.47 |
| PPO | 0.48 |
| Market Risk Indicator (MRI) | 0.90 (High Investment Recommended) |

**6. Expected Return**
Expected Return: -2.00% (Expected excess return compared to S&P 500 if invested long-term (more than 2 years))

**7. Recent News & Significant Events**
- [2026-01-22] Amgen stock hits 52-week high at $346.41
- [2026-01-22] Amgen: A Buy In 2026 On Exciting MariTide Obesity - T2D Potential
- [2026-01-22] Amgen (NASDAQ:AMGN) Hits New 1-Year High
- [2026-01-20] A Look At Amgen (AMGN) Valuation After Strong Q3 Results And Pipeline Momentum
- [2026-01-21] AMGEN INC (NASDAQ:AMGN) Shows High Technical and Setup Ratings for Potential Breakout

**8. Analyst Opinions**
 Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 2.41 (~Buy)
- Opinions: 27
- Target Price (avg/high/low): 331.59 / 425.00 / 180.00

**9. Recent Earnings Analysis**
| Date | EPS | Revenue |
| ---: | ---: | ---: |
| 2025-11-05 | 5.98 | 9.56 B$ |
| 2025-08-06 | 2.66 | 9.18 B$ |
| 2025-05-02 | 3.22 | 8.15 B$ |
| 2024-10-31 | 5.27 | 8.50 B$ |
| 2025-11-05 | 5.27 | 8.50 B$ |

**10. Financial Information**
### Revenue and Profitability
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $9.56B | 67.75% |
| 2025-06-30 | $9.18B | 67.20% |
| 2025-03-31 | $8.15B | 63.58% |
| 2024-12-31 | $9.09B | 65.75% |
| 2024-09-30 | $8.50B | 61.07% |

### Capital and Profitability
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $9.62B | 33.43% |
| 2025-06-30 | $7.43B | 19.28% |
| 2025-03-31 | $6.21B | 27.87% |
| 2024-12-31 | $5.88B | 10.67% |
| 2024-09-30 | $7.53B | 37.60% |

**Comprehensive Analysis:** Amgen has a relatively lower cumulative return rate (79.62%) compared to the S&P 500 (92.53%). The company's market risk indicator (MRI) is 0.90, indicating a high investment recommendation. However, the relative divergence is 32.90%, suggesting that AMGN is currently located at the lower end of the past data fluctuation range. The RSI and PPO indicators are at 64.47 and 0.48, respectively, suggesting a potential buy signal. The expected return is -2.00%, indicating an expected excess return compared to S&P 500 if invested long-term. The analyst consensus is "Buy" with a target price range of $331.59 to $425.00. The recent earnings analysis shows an increase in EPS and revenue. The financial information indicates an increase in revenue and profit margin, while the equity and ROE have shown fluctuations.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.